Skip to content
zameds

Bevacizumab

Sold as Bevacizumab equity, Riqviva, Bevacizumab cipla, Avastin

S4

No structure available

This product's active ingredient could not be matched to a single known compound.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
4
Registrations
8
Schedule source
Consolidated Schedules 06 July 2026

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Equity Pharmaceutical (Pty) LtdCertificate held by Equity Pharmaceuticals (Pty) LtdBevacizumab equity100, 400560466, 560467S4PIPIL
Dr Reddyæs Laboratories (Pty) LtdCertificate held by Dr Reddy’s Laboratories (Pty) Ltd.Riqviva100, 400560604, 560605S4PIPIL
Cipla Medpro (Pty) LtdBevacizumab cipla100, 400570232, 570233S4None
Roche Products (Pty) LtdCertificate held by Roche (Pty) Ltd.Avastin100, 400A390314, A390315S4PIPIL

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Bevacizumab 100 equity

EACH VIAL CONTAINS BEVACIZUMAB 100,0 mg

100Concentrate for solution for infusion56046656/26/0466Approved 4 February 2025RegisteredS4PIPIL
Bevacizumab 400 equity

EACH VIAL CONTAINS BEVACIZUMAB 400,0 mg

400Concentrate for solution for infusion56046756/26/0467Approved 4 February 2025RegisteredS4PIPIL
Riqviva 100

EACH 4,0 ml SOLUTION CONTAINS BEVACIZUMAB 100,0 mg

100Concentrate for solution for infusion56060456/26/0604Approved 15 August 2024RegisteredS4PIPIL
Riqviva 400

EACH 16,0 ml SOLUTION CONTAINS BEVACIZUMAB

400Concentrate for solution for infusion56060556/26/0605Approved 15 August 2024RegisteredS4PIPIL
Bevacizumab 100 cipla

EACH VIAL CONTAINS BEVACIZUMAB 100 mg

10057023257/30.1/0232RegisteredS4None
Bevacizumab 400 cipla

EACH VIAL CONTAINS BEVACIZUMAB 400 mg

40057023357/30.1/0233RegisteredS4None
Avastin 100

EACH 1,0 ml SOLUTION CONTAINS BEVACIZUMAB 25,0 mg

100Concentrate solution for infusionA390314A39/26/0314Approved 19 April 2022RegisteredS4PIPIL
Avastin 400

EACH 1,0 ml SOLUTION CONTAINS BEVACIZUMAB 25,0 mg

400Concentrate solution for infusionA390315A39/26/0315Approved 19 April 2022RegisteredS4PIPIL

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Bevacizumab

  • S4: Bevacizumab

    Consolidated Schedules 06 July 2026, line 5491

Pharmacological class: Cytostatic agents (class 26)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsBevacizumab 100 equity, Equity Pharmaceutical (Pty) LtdPatient information leaflet (PIL)For patients and carersBevacizumab 100 equity, Equity Pharmaceutical (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles